Search research articles
Contact Us
Filters
Showing results (11-20 of 39) with videos related to
Page
of 4
Sort By:
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
May 7, 2020
Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials
Shrita Patel, Anne Hickman, Robert Frederich, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
February 10, 2023
Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity
Linong Ji, Jie Liu, Zhi Jin Xu, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
March 15, 2021
Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV
Matthew J Budoff, Timothy M E Davis, Alexandra G Palmer, et al.
Postgraduate Medicine
|
May 14, 2010
A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes
Robert Frederich, John H Alexander, Fred T Fiedorek, et al.
Clinical Therapeutics
|
October 4, 2005
Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes
John B Buse, Cindy J Rubin, Robert Frederich, et al.
Kidney International Reports
|
August 15, 2022
Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A <i>post hoc</i> Analysis from the Randomized VERTIS CV Trial
David Z I Cherney, Samuel Dagogo-Jack, Francesco Cosentino, et al.
The Journal of Clinical Endocrinology and Metabolism
|
January 26, 2023
Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV
Samuel Dagogo-Jack, Robert Frederich, Jie Liu, et al.
Diabetes, Obesity & Metabolism
|
March 2, 2022
The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV
David Z I Cherney, Francesco Cosentino, Richard E Pratley, et al.
Diabetes, Obesity & Metabolism
|
March 10, 2022
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV
Samuel Dagogo-Jack, Christopher P Cannon, David Z I Cherney, et al.
American Journal of Nephrology
|
June 12, 2022
Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial
David Z I Cherney, Francesco Cosentino, Samuel Dagogo-Jack, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 39) with videos related to
Sort By:
Page
of 4
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
May 7, 2020
Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials
Shrita Patel, Anne Hickman, Robert Frederich, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
February 10, 2023
Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity
Linong Ji, Jie Liu, Zhi Jin Xu, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
March 15, 2021
Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV
Matthew J Budoff, Timothy M E Davis, Alexandra G Palmer, et al.
Postgraduate Medicine
|
May 14, 2010
A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes
Robert Frederich, John H Alexander, Fred T Fiedorek, et al.
Clinical Therapeutics
|
October 4, 2005
Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes
John B Buse, Cindy J Rubin, Robert Frederich, et al.
Kidney International Reports
|
August 15, 2022
Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A <i>post hoc</i> Analysis from the Randomized VERTIS CV Trial
David Z I Cherney, Samuel Dagogo-Jack, Francesco Cosentino, et al.
The Journal of Clinical Endocrinology and Metabolism
|
January 26, 2023
Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV
Samuel Dagogo-Jack, Robert Frederich, Jie Liu, et al.
Diabetes, Obesity & Metabolism
|
March 2, 2022
The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV
David Z I Cherney, Francesco Cosentino, Richard E Pratley, et al.
Diabetes, Obesity & Metabolism
|
March 10, 2022
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV
Samuel Dagogo-Jack, Christopher P Cannon, David Z I Cherney, et al.
American Journal of Nephrology
|
June 12, 2022
Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial
David Z I Cherney, Francesco Cosentino, Samuel Dagogo-Jack, et al.
Page
of 4